The defendants named in the lawsuits include Barr Laboratories, Cobalt Laboratories, Lupin, Orchid Chemicals & Pharmaceuticals, Teva Pharmaceuticals USA, Upsher-Smith Laboratories, Wockhardt and related companies and subsidiaries thereof.
Under the terms of the agreement, Jerini will use its peptides-to-drugs (P2D) technology platform to identify and develop a specific binding molecule for protein purification, which potentially offers
This ongoing trial has been designed to assess the efficacy of TG4010 (MVA-MUC1-IL2) in combination with cisplatin and gemcitabine compared to the chemotherapy regimen alone. The patients in
The FDA’s revised action date for methylnaltrexone is now April 30, 2008. The FDA, in its review of this new drug application (NDA), requested the results from a
The acceptance of the new drug application (NDA), which was submitted on October 31, 2007, means the FDA has made an initial determination that the NDA is sufficiently
The company said that the approval of the general hemostasis in surgery indication is based on the submission of clinical data related to three pivotal studies conducted in
Under their collaboration, both the costs and profits of this program will be shared between GTC and LFB. LFB will fund the final $500,000 license fee payment due
Under the terms of the agreement, Animas will contribute up to $750,000 to DexCom to offset certain development, clinical and regulatory expenses. The agreement is non-exclusive and does
These contracts, which are with an international biotechnology company, cover regulatory submission services, support of new clinical trials, and changes-of-scope for existing studies. The therapeutic areas covered in
CellzDirect provides hepatocyte-based cell products and related services used in the testing of new drugs. The transaction is subject to customary closing conditions and is expected to close
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.